SynAct Q4 2024: Successful Rights Issue Funds 2025 - Redeye
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January. This will fund 2025 and the recruitment of 240 patients in the phase IIb study Advance.
ANNONS
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January. This will fund 2025 and the recruitment of 240 patients in the phase IIb study Advance.